Study Rationale: Persistent activation of the immune cells that reside in the brain leads to a state of chronic inflammation that contributes to the degeneration of neurons in Parkinson’s disease (PD). We have identified a novel inflammatory target in the brain and designed an inhibitor that enters the brain to reduce neuroinflammation and neurodegeneration.
Hypothesis: This study aims to validate the efficacy of our anti-inflammatory preclinical candidate drug in preclinical models of PD.
Study Design: Initial experiments will apply our novel anti-inflammatory drug to human and mouse inflammatory cells to determine the minimal effective dose required to inhibit inflammation. The ability of the anti-inflammatory drug to reduce inflammation in the brain will then be determined in two preclinical models of PD. If reduced brain inflammation is observed in these models — which are induced by acute exposure to different toxins — the ability of the anti-inflammatory drug to improve PD-related motor performance will then be investigated in a long-term preclinical model of the disease.
Impact on Diagnosis/Treatment of Parkinson’s disease: Therapy with an anti-inflammatory drug will provide a unique, neuroprotective, disease-modifying approach for the treatment of PD.
Next Steps for Development: Demonstration of efficacy in acute and long-term preclinical models will complete the preclinical package and allow clinical development in people with PD to proceed.
SIGN UP FOR EMAIL UPDATES
Get Parkinson’s Research News, Foundation Updates, Clinical Trials and more.